Best of the Week
Most Popular
1. Investing in a Bubble Mania Stock Market Trending Towards Financial Crisis 2.0 CRASH! - 9th Sep 21
2.Tech Stocks Bubble Valuations 2000 vs 2021 - 25th Sep 21
3.Stock Market FOMO Going into Crash Season - 8th Oct 21
4.Stock Market FOMO Hits September Brick Wall - Evergrande China's Lehman's Moment - 22nd Sep 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
7.AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
8.Why Silver Price Could Crash by 20%! - 5th Oct 21
9.Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
10.Global Stock Markets Topped 60 Days Before the US Stocks Peaked - 23rd Sep 21
Last 7 days
Best AI Tech Stocks ETF and Investment Trusts - 19th Oct 21
Gold Mining Stocks: Will Investors Dump the Laggards? - 19th Oct 21
The Most Exciting Medical Breakthrough Of The Decade? - 19th Oct 21
Prices Rising as New Dangers Point to Hard Assets - 19th Oct 21
It’s not just Copper; GYX indicated cyclical the whole time - 19th Oct 21
Chinese Tech Stocks CCP Paranoia, VIES - Variable Interest Entities - 19th Oct 21
Inflation Peaked Again, Right? - 19th Oct 21
Gold Stocks Bouncing Hard - 19th Oct 21
Stock Market New Intermediate Bottom Forming? - 19th Oct 21
Beware, Gold Bulls — That’s the Beginning of the End - 18th Oct 21
Gold Price Flag Suggests A Big Rally May Start Soon - 18th Oct 21
Inflation Or Deflation – End Result Is Still Depression - 18th Oct 21
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector - 18th Oct 21
US Economy and Stock Market Addicted to Deficit Spending - 17th Oct 21
The Gold Price And Inflation - 17th Oct 21
Went Long the Crude Oil? Beware of the Headwinds Ahead… - 17th Oct 21
Watch These Next-gen Cloud Computing Stocks - 17th Oct 21
Overclockers UK Custom Built PC 1 YEAR Use Review Verdict - Does it Still Work? - 16th Oct 21
Altonville Mine Tours Maze at Alton Towers Scarefest 2021 - 16th Oct 21
How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
The Only way to Crush Inflation (not stocks) - 14th Oct 21
Why "Losses Are the Norm" in the Stock Market - 14th Oct 21
Sub Species Castle Maze at Alton Towers Scarefest 2021 - 14th Oct 21
Which Wallet is Best for Storing NFTs? - 14th Oct 21
Ailing UK Pound Has Global Effects - 14th Oct 21
How to Get 6 Years Life Out of Your Overclocked PC System, Optimum GPU, CPU and MB Performance - 13th Oct 21
The Demand Shock of 2022 - 12th Oct 21
4 Reasons Why NFTs Could Be The Future - 12th Oct 21
Crimex Silver: Murder Most Foul - 12th Oct 21
Bitcoin Rockets In Preparation For Liftoff To $100,000 - 12th Oct 21
INTEL Tech Stock to the MOON! INTC 2000 vs 2021 Market Bubble WARNING - 11th Oct 21
AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
Stock Market Wall of Worry Meets NFPs - 11th Oct 21
Stock Market Intermediate Correction Continues - 11th Oct 21
China / US Stock Markets Divergence - 10th Oct 21
Can US Save Taiwan From China? Taiwan Strait Naval Battle - PLA vs 7th Fleet War Game Simulation - 10th Oct 21
Gold Price Outlook: The Inflation Chasm Between Europe and the US - 10th Oct 21
US Real Estate ETFs React To Rising Housing Market Mortgage Interest Rates - 10th Oct 21
US China War over Taiwan Simulation 2021, Invasion Forecast - Who Will Win? - 9th Oct 21
When Will the Fed Taper? - 9th Oct 21
Dancing with Ghouls and Ghosts at Alton Towers Scarefest 2021 - 9th Oct 21
Stock Market FOMO Going into Crash Season - 8th Oct 21
Scan Computers - Custom Build PC 6 Months Later, Reliability, Issues, Quality of Tech Support Review - 8th Oct 21
Gold and Silver: Your Financial Main Battle Tanks - 8th Oct 21
How to handle the “Twin Crises” Evergrande and Debt Ceiling Threatening Stocks - 8th Oct 21
Why a Peak in US Home Prices May Be Approaching - 8th Oct 21
Alton Towers Scarefest is BACK! Post Pandemic Frights Begin, What it's Like to Enter Scarefest 2021 - 8th Oct 21
AJ Bell vs II Interactive Investor - Which Platform is Best for Buying US FAANG Stocks UK Investing - 7th Oct 21
Gold: Evergrande Investors' Savior - 7th Oct 21
Here's What Really Sets Interest Rates (Not Central Banks) - 7th Oct 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

SILO Stock The Most Undervalued Play In Psychedelic

Companies / BioTech Dec 16, 2020 - 03:08 PM GMT

By: Joshua_Rodriguez


Psychedelics has become a hot topic among the investing community. They’ve been around for some time, and for the most part, these party favors found in dorm rooms are looked at in a negative connotation.

But what if I told you that psychedelics could be the answer to some of the most difficult-to-treat medical conditions.

I know it sounds strange, but oftentimes, there’s therapeutic benefit found in the strangest things, and believe it or not, psychedelics have been used as a medicine for hundreds of years.

No, you’re not going to go to the doctor with a flu and be prescribed psilocybin or LSD, but medicine men among various cultures, including Native Americans, have used these mind-altering compounds as an option for the treatment of various ailments. So, psychedelics as a medicine aren’t anything new.

Today, there are a handful of biotech companies looking to take our understanding of how psychedelics can improve things like cognition in Alzheimer’s and Parkinson’s disease patients, frame of thought in depression patients, and ability to live a relatively normal life in PTSD patients.

Ultimately, there are several ailments that compounds like psilocybin, LSD, and MDMA may provide the answer for.

Of course, medicine is big business. So, should these psychedelic therapies prove effective, they’ll come with the potential to produce tremendous profitability for the companies that develop them. As such, investor interest surrounding this concept has been ramping up in recent years.

With only a handful of biotechs studying psychedelics as a therapeutic option, and investor demand running high in the space, it’s not surprising that the vast majority of companies focused on this compelling science are overvalued on Wall Street.

Nonetheless, there’s one company in the space that has a clear and overwhelming undervaluation that I believe represents a tremendous opportunity for investors.

That company is Silo Pharma (OTCQB: SILO).

Skip to What You Want to Read

(Links below will jump to headings in the article. This section is required for formatting on the publication the article was written for.)

What Is Silo Pharma?

What Is Psilocybin?

SILO Is Tapping Into Massive Markets

Silo Pharma’s Closest Comp Climbed Over 700% This Year

What’s Next for SILO?

Final Thoughts

What Is Silo Pharma?

Silo Pharma is a clinical-stage biotechnology company that’s focused on the use of psychedelics as a treatment option for some of the world’s most debilitating psychological conditions.

The company is working on putting together a Scientific Advisory Board like nothing else seen in a publicly traded company. However, a Scientific Advisory Board means nothing if you’re not in the process of developing something meaningful.

Recently Silo Pharma announced that it would be hitting the clinic for a Phase 2B clinical study. In particular, the study is designed to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunction in Parkinson’s disease.

Importantly, SILO won’t have to foot the bill on this one by themselves. In fact, this is an investigator-sponsored study, with Dr. Kim Kuypers, Associate Professor of the Department of Neurology and Psychopharmacology at Maastricht University, will act as the Investigator Sponsor of the Phase 2B clinical study.

The company is also researching ways to treat conditions like fibromyalgia and general anxiety disorder (GAD) using psychedelic therapies. For more information on Silo Pharma, click here.

What Is Psilocybin?

Psilocybin is the active ingredient found in magic mushrooms and one of the most important compounds being addressed by Silo Pharma. Used by medicine men for hundreds of years, there is plenty of literature that backs psilocybin up as a potential treatment for psychiatric disorders, personal and spiritual development, and creative enhancement.

More recently, the compound has been the subject of several clinical studies, which have only served to prove that old-school medicine men from lesser-developed cultures are onto something here.

SILO Is Tapping Into Massive Markets

Should Silo Pharma be successful in proving that psychedelic compounds are an effective treatment for the ailments it’s targeting, it will tap into massive markets. Just take a look below:

  1. Parkinson’s Disease. By 2025, it is expected that the Parkinson’s disease treatment market will grow to be worth about $6 billion annually.
  2. Fibromyalgia. Fibromyalgia treatments are expected to drive more than $3.6 billion in revenue for the companies that provide them by the year 2026.
  3. GAD. Finally, the GAD market is expected to grow to be worth $7.5 billion by 2023.

Keep in mind, when we talk about SILO, we’re talking about a stock with a market cap of just $35 million! Should the company tap into any of these markets, even in a very small way, it would be enough to generate significant revenue.

Silo Pharma’s Closest Comp Climbed Over 700% This Year

With a title like, “SILO Stock: The Most Undervalued Play In Psychedelics,” it’s only fitting that I point to the extreme undervaluation of the stock out here.

To get a feel for just how undervalued the stock is, all you need to do is look at its closest comparable stock, Mind Medicine (OTC: MMEDF). Like Silo Pharma, Mind Medicine is currently in Phase 2 development of psychedelics as a therapeutic option.

In particular, the company is assessing small doses of LSD as a potential option for patients with anxiety, and producing promising results in the process. However, the stock has already caught the attention of investors, and the potential for a dramatic run in any near-term has largely come and gone.

In fact, this year alone, MMEDF has climbed by more than 700%. Today, the company is worth more than $900 million. That’s right, this Phase 2 clinical-stage biotech is closing in on a billion dollar valuation.

At the same time, Silo Pharma is sitting on the same stage, but due to the fact that it’s not in the spotlight, remains overwhelmingly undervalued. While MMEDF trades with a market cap over $900 million, SILO stock trades with a market cap of just $35 million.

What’s Next for SILO?

Moving forward, Silo Pharma is one to watch closely. First and foremost, the Phase 2B clinical study that’s just around the corner will likely act as a major catalyst. With plenty of literature suggesting strong potential efficacy of psychedelics among the Parkinson’s disease patient population, there’s a high probability of success.

Should the study be successful, it will set the stage for tremendous growth ahead. After all, should the study go well, the company will likely move into late-stage development, garnering the attention of investors and leading to a potential run the likes of what we saw from MMEDF so far this year.

Final Thoughts

The bottom line here is simple. Psychedelics are far more than recreational drugs. Throughout history, they have been used to address some of the most debilitating conditions by medicine men around the world. Today, the scientific community is catching onto the potential power of these compounds.

At the moment, there are only a few companies assessing these compounds, with the vast majority of them being heavily overvalued. However, SILO seems to be the one play in the space that’s heavily undervalued, creating the potential for dramatic gains ahead.

This is a paid advertisement. The views expressed above are those of the author. Silo Pharma played no role in the development or editing of this article.

By Joshua Rodriguez

© 2020 Copyright Joshua Rodriguez - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in